Company: PRME
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001628280-25-018704
Chunk: 56

Company: Prime Medicine, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 56
---
 the term of the BMS Collaboration Agreement continues until expiration of the last royalty term for the applicable product in the applicable country. The BMS Collaboration Agreement is subject to customary termination provisions, including termination by a party for the other party’s uncured, material breach.

<div align='center'>35</div>

Stock Purchase Agreement

In September 2024, we entered into a stock purchase agreement with BMS (the “BMS Purchase Agreement”), pursuant to which we agreed to issue and sell, and BMS agreed to purchase, 11,006,163 shares of our common stock (the “BMS Shares”) for an aggregate purchase price of $55.0 million pursuant to the terms and conditions thereof. Pursuant to the terms of the BMS Purchase Agreement, BMS has agreed not to, directly or indirectly, sell or transfer any of the BMS Shares until September 30, 2027 subject to specified conditions and exceptions. In addition, we agreed, among other things, to file with the SEC a registration statement covering the resale of the BMS Shares and to use commercially reasonable efforts to cause such registration statement to become effective on or prior to ninety (90) calendar days after closing. We filed the registration statement on Form S-3 covering the resale of the BMS Shares with the SEC on December 13, 2024, which became effective on December 20, 2024.

We have also agreed to customary indemnification obligations under the BMS Purchase Agreement.

#### Consulting Agreement with David Liu
Pursuant to a consulting agreement, dated September 13, 2019, as amended on October 22, 2021 and July 31, 2024, with David Liu (the “Liu Consulting Agreement”), we agreed to pay Dr. Liu an annual fee of $150,000 and to reimburse Dr. Liu’s reasonable business expenses. Dr. Liu is a beneficial owner of more than 5% of our voting securities. Dr. Liu agreed to provide services, including serving as Chairman of our Scientific Advisory Board and providing certain advisory services.

The Liu Consulting Agreement terminated on September 1, 2024. From January 1, 2023 through the termination date, we paid Dr. Liu $250,000 under the Liu Consulting Agreement.

#### Advisory Services Agreement with Jeffrey Marrazzo
Pursuant to an advisory services agreement with Jeffrey Marrazzo, a member of our Board of Directors (the “Marrazzo Agreement”), dated February 29, 2024